Diana Garcia-del- Barco

Prof. Dr. Diana Garcia-del- Barco


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 February 2010 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco
HPHéctor Pérez-Saad
Héctor Pérez-Saad
VRValia Rodríguez
Valia Rodríguez
JMJavier Marín
Javier Marín
VFViviana Falcón
Viviana Falcón
JBJorge Berlanga
Jorge Berlanga

26 September 2016 in Neurological Research
Verified
Journal Article
Closed access
NSN. Subirós
N. Subirós
HPH. Pérez-Saad
H. Pérez-Saad
LAL. Aldana
L. Aldana
CGC. L. Gibson
C. L. Gibson
WBW. S. Borgnakke
W. S. Borgnakke
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco
Background: Combined therapy with epidermal growth factor (EGF) and growth hormone-releasing peptide 6 (GHRP-6) in stroke models has accumulated evidence of neuroprotective effects from several studies, but needs further support before clinical translation. Comparing EGF + GHRP-6 to hypothermia, a gold neuroprotection standard, may contribute to this purpose. Objectives: The aims of this study were to compare the neuroprotective effects of a combined therapy based on EGF + GHRP-6 with hypothermia in animal models of (a) global ischemia representing myocardial infarction and (b) focal brain ischemia representing ischemic stroke. Methods: (a) Global ischemia was induced in Mongolian gerbils by a 15-min occlusion of both carotid arteries, followed by reperfusion. (b) Focal brain ischemia was achieved by intracerebral injection of endothelin 1 in Wistar rats. In each experiment, three ischemic treatment groups – vehicle, EGF + GHRP-6, and hypothermia – were compared to each other and to a sham-operated control group. End points were survival, neurological scores, and infarct volume. Results: (a) In global ischemia, neurological score at 48–72 h, infarct volume, and neuronal density of hippocampal CA1 zone in gerbils treated with EGF + GHRP-6 were similar to the hypothermia-treated group. (b) In focal ischemia, the neurologic score and infarct volume of rats receiving EGF + GHRP-6 were also similar to animals in the hypothermia group. Discussion: With hypothermia being a good standard neuroprotectant reference, these results provide additional proof of principle for EGF and GHRP-6 co-administration as a potentially neuroprotective stroke therapy.

8 June 2017 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
HPH. Perez‐Saad
H. Perez‐Saad
NSN. Subiros
N. Subiros
JBJ. Berlanga
J. Berlanga
LAL. Aldana
L. Aldana
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco

1 January 2011 in Restorative Neurology and Neuroscience
Verified
Journal Article
Closed access
PDF file
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco
EMEnrique Montero
Enrique Montero
RCRosa M. Coro-Antich
Rosa M. Coro-Antich
EBEnma Brown
Enma Brown
JSJosé Suarez-Alba
José Suarez-Alba
JBJorge Berlanga
Jorge Berlanga
Purpose: Multiple sclerosis is a complex and devastating autoimmune disease of the central nervous system. Up to now, a constellation of candidate drugs have been evaluated with no major success. Experimental Autoimmune Encephalitis (EAE) is the animal counterpart that reproduces critical features of the human MS process. The aim of the present work is to study a possible therapeutic effect of epidermal growth factor (EGF) and growth hormone releasing peptide-6 (GHRP6 coadministration in mild and severe EAE. Methods: Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOGp35–35, respectively. EGF and GHRP6 alone or combined were administered in therapeutic and prophylactic schedules. A clinical score was established to follow-up the animals during the disease period. Malondialdehyde (MDA) serum concentration and insulin like growth factor-1 (IGF-1) relative level from brain tissue were determined. Results: Only the combined EGF+GHRP6 therapy reduced the clinical score in mild as well in severe EAE forms. The combination also improved the survival rate in nearly 100% of the severe EAE animals. In addition to these effects, there was an increase in the brain IGF-1 transcript and a decrease of serum MDA. Conclusions: EGF+GHRP6 proved to be effective in improving the natural course of both mild and severe EAE. Accordingly, the treatment reduces inflammatory infiltration and microvascular damage, which may be associated to the attenuation of the lipid peroxidation process and the transcriptional enhancement of IGF-1, a major pro-survival factor for brain cells.

4 April 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
FHFrancisco Hernández-Bernal
Francisco Hernández-Bernal
DEDonner Estenoz-García
Donner Estenoz-García
JGJuan H. Gutiérrez-Ronquillo
Juan H. Gutiérrez-Ronquillo
YMYenima Martín-Bauta
Yenima Martín-Bauta
KCKaren Catasús-Álvarez
Karen Catasús-Álvarez
\H\R\Nfrancisco Hern
\R\Nfrancisco Hern
Objective: This study tested the hypothesis that a neuroprotective combined therapy based on epidermal growth factor (EGF) and growth hormone-releasing hexapeptide (GHRP6) could be safe for acute ischemic stroke patients, admitting up to 30% of serious adverse events (SAE) with proven causality.Methods: A multi-centric, randomized, open-label, controlled, phase I-II clinical trial with parallel groups was conducted (July 2017 to January 2018). Patients aged 18–80 years with a computed tomography-confirmed ischemic stroke and less than 12 h from the onset of symptoms were randomly assigned to the study groups I (75 μg rEGF + 3.5 mg GHRP6 i.v., n=10), II (75 μg rEGF + 5 mg GHRP6 i.v., n=10), or III (standard care control, n=16). Combined therapy was given BID for 7 days. The primary endpoint was safety over 6 months. Secondary endpoints included neurological (NIHSS) and functional [Barthel index and modified Rankin scale (mRS)] outcomes.Results: The study population had a mean age of 66 ± 11 years, with 21 men (58.3%), a baseline median NIHSS score of 9 (95% CI: 8–11), and a mean time to treatment of 7.3 ± 2.8 h. Analyses were conducted on an intention-to-treat basis. SAEs were reported in 9 of 16 (56.2%) patients in the control group, 3 of 10 (30%) patients in Group I (odds ratio (OR): 0.33; 95% CI: 0.06–1.78), and 2 of 10 (20%) patients in Group II (OR: 0.19; 95% CI: 0.03–1.22); only two events in one patient in Group I were attributed to the intervention treatment. Compliance with the study hypothesis was greater than 0.90 in each group. Patients treated with EGF + GHRP6 had a favorable neurological and functional evolution at both 90 and 180 days, as evidenced by the inferential analysis of NIHSS, Barthel, and mRS and by their moderate to strong effect size. At 6 months, proportion analysis evidenced a higher survival rate for patients treated with the combined therapy. Ancillary analysis including merged treated groups and utility-weighted mRS also showed a benefit of this combined therapy.Conclusion: EGF + GHRP6 therapy was safe. The functional benefits of treatment in this study supported a Phase III study.Clinical Trial Registration: RPCEC00000214 of the Cuban Public Registry of Clinical Trials, Unique identifier: IG/CIGB-845I/IC/1601.